Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.
The Conversation logo

Sean Jennings started taking opioids in 1993 following a complication from a hernia operation that left him in debilitating pain. His GP initially prescribed codeine combined with paracetamol, but the pain persisted. Every day Sean took more and more pills. His GP eventually prescribed stronger opioids than codeine – tramadol, at first, and then morphine. Twenty-five years on, Sean was taking 160mg of morphine every day – a very high dose – but he was still in pain. He was also at high risk of overdosing.

To find out how many people there are like Sean, we conducted a study, synthesising all the published research on high-dose opioids. We found that of 4.2 million people taking prescription opioids in Australia, the UK and the US, over 154,000 were taking high doses. We also found five factors linked to the use of high-dose opioids: being prescribed benzodiazepines (such as Valium), increased visits to emergency departments, depression, unemployment and being male.

Read the full article on The Conversation website, written by Georgia Richards, DPhil Student, Centre for Evidence-Based Medicine (Nuffield Department of Primary Care Health Sciences)

Oxford is a subscribing member of The ConversationFind out how you can write for The Conversation.

Similar stories

New reporting guidelines developed to improve AI in healthcare settings

New reporting guidelines, jointly published in Nature Medicine and the BMJ by Oxford researchers, will ensure that early studies on using Artificial Intelligence (AI) to treat real patients will give researchers the information needed to develop AI systems safely and effectively.

Major boost for Oxford’s mission to counter future pandemic threats

The Moh Family Foundation has given a substantial gift to support the work of Oxford University’s Pandemic Sciences Institute, greatly strengthening its ability to identify and counter future pandemic threats and ensure equitable access to treatments and vaccines around the world.

Three NHSBT research units launch at University of Oxford

The NIHR has awarded three new Blood and Transplant Research Units (BTRUs) to the University of Oxford.

Fourth COVID-19 vaccine dose provides stronger immunity boost than third dose, shows UK study

COVID-19 vaccines given as fourth doses in the UK offer excellent boosting immunity protection, according to the latest results from a nationwide NIHR-supported study.

COVID-19’s high blood clot risk

A recent study of patient health records found that around 1 in 100 people with COVID-19 had a venal or arterial thrombosis, with rates higher still among males, and particularly for those hospitalised.

Medical Sciences Division receives REF 2021 results

Today the UK Funding Bodies have published the outcomes of the recent national research assessment exercise, the Research Excellence Framework (REF) 2021. REF is the UK-wide assessment of research in universities, and provides an expert evaluation of the quality of the research outputs, impact and environment at subject level in each university.